HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1′ substituent

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 19, 2003, Pages 3323-3326

  Duffy, Joseph L ^a   Kirk, Brian A ^a   Kevin, Nancy J ^a   Chapman, Kevin T ^a   Schleif, William A ^a   Olsen, David B ^a   Stahlhut, Mark ^a   Rutkowski, Carrie A ^a   Kuo, Lawrence C ^a   Jin, Lixia ^a   Lin, Jiunn H ^a   Emini, Emilio A ^a   Tata, James R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ISOPROTEIN; NITROGEN DERIVATIVE; PROTEINASE INHIBITOR; PYRIDYL NITROGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SOLUBILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; LIQUID; NONHUMAN; VIRUS INHIBITION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 10744221384     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00680-2     Document Type: Article

References (17)

1. Kempf, D. J.; Molla, A.; Hsu, A. In Antiretroviral Therapy; De Clercq, E., Ed., ASM: Washington, DC, 2001; p 147.
2. Romano L., Venturi G., Giomi S., Pippi L., Valensin P.E., Zazzi M. J. Med. Virol. 66:2002;143.
3. Duffy, J. L.; Rano, T. A.; Kevin, N. J.; Chapman, K. T.; Schleif, W. A.; Olsen, D. B.; Stahlhut, M.; Rutkowski, C. A.; Kuo, L. C.; Jin, L.; Lin, J. H.; Emini, E. A. and Tata, J. R. Bioorg. Med. Chem. Lett. 2003, 13, 2569.
4. (a) This strategy was successfully employed during the development of indinavir. See: Dorsey B.D., McDaniel S.L., Levin R.B., Vacca J.P., Darke P.L., Zugay J.A., Emini E.A., Schleif W.A., Lin J.H., Chen I.-W., Holloway M.K., Anderson P.S., Huff J.R. Bioorg. Med. Chem. Lett. 4:1994;2769.
5. (b) Dorsey B.D., McDonough C., McDaniel S.L., Levin R.B., Newton C.L., Hoffman J.M., Darke P.L., Zugay-Murphy J.A., Emini E.A., Schleif W.A., Olsen D.B., Stahlhut M.W., Rutkowski C.A., Kuo L.C., Lin J.H., Chen I-W., Michelson S.R., Holloway M.K., Huff J.R., Vacca J.P. J. Med. Chem. 43:2000;3386.
6. Maligres P.E., Weissman S.A., Upadhyay V., Cianciosi S.J., Reamer R.A., Purick R.M., Sager J., Rossen K., Eng K.K., Askin D., Volante R.P., Reider P.J. Tetrahedron. 52:1996;3327.
7. Askin D., Eng K.K., Rossen K., Purick R.M., Wells K.M., Volante R.P., Reider P.J. Tetrahedron Lett. 35:1994;673.
8. Hansen K.B., Rabbat P., Springfield S.A., Devine P.N., Grabowski E.J.J., Reider P.J. Tetrahedron Lett. 42:2001;8743.
9. (a) Olsen D.B., Stahlhut M.W., Rutkowski C.A., Schock H.B., vanOlden A.L., Kuo L.C. J. Biol. Chem. 274:1999;23699.
10. (b) Condra J.H., Holder D.J., Schleif W.A., Blahy O.M., Danovich R.M., Gabyelski L.J., Graham D.J., Laird D., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Yang T., Chodakewitz J.A., Deutsch P.J., Leavitt R.Y., Massari F.E., Mellors J.W., Squires K.E., Steigbigel R.T., Teppler H., Emini E.A. J. Virol. 70:1996;8270.
11. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., Sardana V.V., Schlabach A.J., Graham P.I., Condra J.H., Gotlib L., Holloway M.K., Lin J., Chen I.-W., Vastag K., Ostovic D., Anderson P.S., Emini E.A., Huff J.R. Proc. Nat. Acad. Sci. U.S.A. 91:1994;4096.
12. (a) The use of animals was done under the purview of an Institutional Animal Care and Use Committee, and all applicable regulations and laws pertaining to the use of laboratory animals were followed. For experimental methods for both in vitro and in vivo pharmacokinetic investigations, see: Chiba M., Hensleigh M., Nishime J.A., Balani S.K., Lin J.H. Drug Metab. Disp. 24:1996;307.
13. (b) Lin J.H., Chiba M., Balani S.K., Chen I.-W., Kwei G.Y.-S., Vastag K.J., Nishime J.A. Drug Metab. Disp. 24:1996;1111.
14. Dorsey B.D., Levin R.B., McDaniel S.L., Vacca J.P., Guare J.P., Darke P.L., Zugay J.A., Emini E.A., Schleif W.A., Quintero J.C., Lin J.H., Chen I.-W., Holloway M.K., Fitzgerald P.M.D., Axel M.G., Ostovic D., Anderson P.S., Huff J.R. J. Med. Chem. 37:1994;3443.
15. Synthesis of the benzofuran derivatives was accomplished by modification of the corresponding 8-iodobenzofuran intermediate. See: Cheng Y., Zhang F., Rano T.A., Lu Z., Schleif W.A., Gabryelshi L., Olsen D.B., Stahlhut M., Rutkowski C.A., Lin J.H., Jin L., Emini E.A., Chapman K.T., Tata J.R. Bioorg. Med. Chem. Lett. 12:2002;2419.
16. 1′ sites simultaneously results in decreased efficacy in the viral spread assay. See ref 4a.
17. Williams G.C., Sinko P.J. Adv. Drug Deliv. Rev. 39:1999;211.